

Table 1. Subject groups and treatment variables.

Group	Group name	N	MPTP Rx	Time between MPTP and Tx	Time from Tx to death	Sham Tx	Immuno-suppression	No. cell conc./inj site	Total no. cells Tx/site	Cell line details	Histology
1	Behavioral study	3	2.25 mg/kg	3.5 mos	4 mos	Y	Cyclo 3/3	0	Sham		Fig. 5
1	Behavioral study	5	2.25 mg/kg	3.5 mos	4 mos	N	Cyclo 2/5	100,000/ul (10 ul)	1.00E+06	H1	Figs. 2 and 3 SI. Fig. 9
2	4-month outcome	1*	2.25 mg/kg	3.5 mos	4 mos	N	Cyclo	100,000/ul (10 ul)	1.00E+06	H1	Fig. 5 and SI Fig. 9
2	4-month outcome	3*	2.25 mg/kg	3.5 mos	4 mos	N	No	100,000/ul (10 ul)	1.00E+06	HFB2050	Fig. 5 and SI Fig. 9
3	7-month outcome	5	2.25 mg/kg	6 mos	7 mos	N	Cyclo 5/5	50,00/ul (20 ul)	1.00E+06	HFB2050	Fig. 5 and SI Fig. 9
4	Control monkeys	4	0	NA	NA	Y	No	0	0		Fig. 5 and SI Figs. 9 and 10
5	7-month triple immuno	6	1.5 mg/kg	2	7-8 mos	N	Triple 6/6	40-50K/μl (15-35 μl)**	1.25E+06 to 8.75E+06	HFB2050	Figs. 4 and 5 and SI Figs. 7 and 9
6	alpha-synuclein	2***	2.25 mg/kg	4.5 mos	1 mo	N	Cyclo	50,000/ul (10 ul)	5.00E+05	HFB2050	Fig. 5 and SI Fig. 10
Total number		29									

*Plus a subset of the monkeys from the Behavioral Study, Group 1.

** Injected into left SN instead of right SN unilaterally.

***Plus control monkeys from Group 1 and Group 4; of the NSC-injected monkeys, two were MPTP treated and two were not. Altogether, eight monkeys were studied for alpha-synuclein expression.